Qiming Venture Partners Portfolio Company Insilico Medicine Successfully Lists on Hong Kong Exchanges and Clearing Limited
In 2019, Qiming Venture Partners led Insilico Medicine's Series B financing and continued to back the company through its Series C and D rounds. Prior to the IPO, Qiming Venture Partners held approximately 7% of Insilico Medicine's shares, making it one of the company's most important institutional investors.









